Eaton Vance Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $312M | Sell |
7,125,127
-487,555
| -6% | -$23.7M | 0.46% | 44 |
|
|
2022
Q2 | $399M | Sell |
7,612,682
-498,886
| -6% | -$25.4M | 0.56% | 33 |
|
|
2022
Q1 | $420M | Buy |
8,111,568
+2,864,462
| +55% | +$149M | 0.48% | 41 |
|
|
2021
Q4 | $310M | Buy |
5,247,106
+951,506
| +22% | +$47.1M | 0.38% | 53 |
|
|
2021
Q3 | $180M | Buy |
4,295,600
+11,770
| +0.3% | +$521K | 0.25% | 86 |
|
|
2021
Q2 | $168M | Buy |
4,283,830
+16,994
| +0.4% | +$661K | 0.23% | 95 |
|
|
2021
Q1 | $155M | Sell |
4,266,836
-283,001
| -6% | -$10M | 0.23% | 100 |
|
|
2020
Q4 | $167M | Sell |
4,549,837
-307,370
| -6% | -$11.3M | 0.26% | 93 |
|
|
2020
Q3 | $169M | Sell |
4,857,207
-174,494
| -3% | -$6.12M | 0.31% | 74 |
|
|
2020
Q2 | $156M | Sell |
5,031,701
-12,231
| -0.2% | -$416K | 0.32% | 73 |
|
|
2020
Q1 | $156M | Sell |
5,043,932
-281,698
| -5% | -$9.6M | 0.38% | 61 |
|
|
2019
Q4 | $198M | Sell |
5,325,630
-952,746
| -15% | -$33.9M | 0.39% | 65 |
|
|
2019
Q3 | $214M | Buy |
6,278,376
+1,285,026
| +26% | +$46.7M | 0.46% | 52 |
|
|
2019
Q2 | $205M | Buy |
4,993,350
+115,443
| +2% | +$4.58M | 0.45% | 53 |
|
|
2019
Q1 | $197M | Sell |
4,877,907
-302,730
| -6% | -$12.1M | 0.45% | 59 |
|
|
2018
Q4 | $215M | Sell |
5,180,637
-1,994,307
| -28% | -$82.8M | 0.56% | 46 |
|
|
2018
Q3 | $300M | Sell |
7,174,944
-1,869,209
| -21% | -$72M | 0.67% | 32 |
|
|
2018
Q2 | $311M | Sell |
9,044,153
-9,363,409
| -51% | -$320M | 0.74% | 25 |
|
|
2018
Q1 | $620M | Buy |
18,407,562
+9,259,419
| +101% | +$318M | 0.77% | 26 |
|
|
2017
Q4 | $314M | Buy |
9,148,143
+243,734
| +3% | +$8.31M | 0.76% | 28 |
|
|
2017
Q3 | $302M | Sell |
8,904,409
-383,206
| -4% | -$12.3M | 0.78% | 27 |
|
|
2017
Q2 | $296M | Sell |
9,287,615
-2,772,181
| -23% | -$87.4M | 0.78% | 24 |
|
|
2017
Q1 | $391M | Sell |
12,059,796
-1,197,858
| -9% | -$37.8M | 1.05% | 15 |
|
|
2016
Q4 | $409M | Buy |
13,257,654
+4,755,192
| +56% | +$145M | 1.15% | 13 |
|
|
2016
Q3 | $273M | Sell |
8,502,462
-1,654,882
| -16% | -$55.3M | 0.79% | 34 |
|
|
2016
Q2 | $339M | Buy |
10,157,344
+6,170,373
| +155% | +$197M | 0.99% | 24 |
|
|
2016
Q1 | $112M | Sell |
3,986,971
-195,137
| -5% | -$5.57M | 0.34% | 90 |
|
|
2015
Q4 | $128M | Buy |
4,182,108
+31,684
| +0.8% | +$997K | 0.38% | 77 |
|
|
2015
Q3 | $124M | Buy |
4,150,424
+419,594
| +11% | +$13.5M | 0.38% | 73 |
|
|
2015
Q2 | $119M | Sell |
3,730,830
-2,027,515
| -35% | -$66.1M | 0.36% | 78 |
|
|
2015
Q1 | $190M | Buy |
5,758,345
+2,163,951
| +60% | +$68.8M | 0.57% | 52 |
|
|
2014
Q4 | $106M | Sell |
3,594,394
-2,109,806
| -37% | -$60.5M | 0.31% | 95 |
|
|
2014
Q3 | $160M | Sell |
5,704,200
-7,220,416
| -56% | -$203M | 0.48% | 61 |
|
|
2014
Q2 | $364M | Sell |
12,924,616
-1,474,738
| -10% | -$42M | 1.08% | 24 |
|
|
2014
Q1 | $439M | Sell |
14,399,354
-3,275,517
| -19% | -$97.7M | 1.29% | 15 |
|
|
2013
Q4 | $514M | Sell |
17,674,871
-3,662,303
| -17% | -$107M | 1.47% | 13 |
|
|
2013
Q3 | $581M | Sell |
21,337,174
-910,897
| -4% | -$24.8M | 1.74% | 5 |
|
|
2013
Q2 | $591M | Buy |
+22,248,071
| New | +$615M | 1.79% | 5 |
|
Other funds holding PFE
Eaton Vance Management's PFE Position: Q3 2022 in Review
Eaton Vance Management reduced its Pfizer (PFE) stake by 6.4% in Q3 2022, selling an estimated $23.7M and leaving 7,125,127 shares worth $312M. The position accounts for 0.46% of the portfolio, ranked #44.
Eaton Vance Management first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $620M in Q1 2018. 3,086 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- Eaton Vance Management held 7,125,127 shares of Pfizer worth $312M as of Q3 2022.
- Eaton Vance Management sold 487,555 Pfizer shares in Q3 2022, an estimated $23.7M.
- Pfizer made up 0.46% of Eaton Vance Management's portfolio in Q3 2022, its #44 holding.
- Eaton Vance Management first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- Eaton Vance Management's Pfizer position peaked at $620M in Q1 2018.
- 3,086 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.